

Raphael Duivenvoorden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7873401/publications.pdf>

Version: 2024-02-01

71
papers

5,452
citations

126858

33
h-index

88593

70
g-index

80
all docs

80
docs citations

80
times ranked

7540
citing authors

#	ARTICLE	IF	CITATIONS
1	Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1140-1151.	0.4	7
2	Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19. <i>Transplantation</i> , 2022, 106, 1012-1023.	0.5	8
3	FC008: Sex Difference in COVID-19 Mortality Risk among Patients on Kidney Function Replacement Therapy. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
4	MO495: A Comparative Study of Patient Mortality During First and Second Waves of Covid-19 Pandemic in Dialysis Patients and Kidney Transplant Recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
5	MO899: The Clinical frailty Scale is Useful for ICU Triage in Dialysis Patients With COVID-19â€“An Eracoda Analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
6	Trained immunity, tolerance, priming and differentiation: distinct immunological processes. <i>Nature Immunology</i> , 2021, 22, 2-6.	7.0	274
7	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 87-94.	0.4	259
8	Pitfalls when comparing COVID-19-related outcomes across studiesâ€“lessons learnt from the ERACODA collaboration. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i14-i20.	1.4	7
9	Prosaposin mediates inflammation in atherosclerosis. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	42
10	COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2094-2105.	0.4	65
11	Renin-Angiotensin System Blockers and the Risk of COVID-19â€“Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1061-1072.	2.2	7
12	Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1839-1850.	1.1	4
13	Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2308-2320.	0.4	3
14	Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. <i>Med</i> , 2021, 2, 1163-1170.e2.	2.2	31
15	Increased Plasma Heparanase Activity in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020, 11, 575047.	2.2	98
16	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. <i>Cell Reports Medicine</i> , 2020, 1, 100146.	3.3	24
17	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1973-1983.	0.4	312
18	Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 786-801.e19.	13.5	101

#	ARTICLE	IF	CITATIONS
19	Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. <i>Nature Nanotechnology</i> , 2020, 15, 398-405.	15.6	42
20	ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2023-2025.	0.4	25
21	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
22	Nanoimmunotherapy to treat ischaemic heart disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 21-32.	6.1	43
23	Atherosclerosis and Diabetic Nephropathy. , 2019, , 357-372.		1
24	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. <i>Nature Biomedical Engineering</i> , 2018, 2, 279-292.	11.6	94
25	Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 527-542.	1.2	149
26	CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease. <i>Cardiovascular Research</i> , 2018, 114, 468-475.	1.8	43
27	Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. <i>Immunity</i> , 2018, 49, 819-828.e6.	6.6	161
28	Imaging Tropoelastin in Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e008147.	1.3	1
29	Arterial and Cellular Inflammation in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1278-1285.	3.0	46
30	Character, Incidence, and Predictors of Knee Pain and Activity After Infrapatellar Intramedullary Nailing of an Isolated Tibia Fracture. <i>Journal of Orthopaedic Trauma</i> , 2016, 30, 135-141.	0.7	14
31	Does Participation in a Randomized Clinical Trial Change Outcomes? An Evaluation of Patients Not Enrolled in the SPRINT Trial. <i>Journal of Orthopaedic Trauma</i> , 2016, 30, 156-161.	0.7	1
32	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6731-E6740.	3.3	95
33	Augmenting drug carrier compatibility improves tumour nanotherapy efficacy. <i>Nature Communications</i> , 2016, 7, 11221.	5.8	111
34	HDL mimetic CER-001 targets atherosclerotic plaques in patients. <i>Atherosclerosis</i> , 2016, 251, 381-388.	0.4	51
35	In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 950-961.	2.3	78
36	Unique Renal Manifestation of Type I Cryoglobulinemia, With Massive Crystalloid Deposits in Glomerular Histiocytes, Podocytes, and Endothelial Cells. <i>American Journal of Clinical Pathology</i> , 2016, 145, 282-285.	0.4	3

#	ARTICLE	IF	CITATIONS
37	Manual versus Automated Carotid Artery Plaque Component Segmentation in High and Lower Quality 3.0 Tesla MRI Scans. PLoS ONE, 2016, 11, e0164267.	1.1	7
38	Increasing the Spatial Resolution of 3T Carotid MRI Has No Beneficial Effect for Plaque Component Measurement Reproducibility. PLoS ONE, 2015, 10, e0130878.	1.1	8
39	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	4.7	173
40	Endothelial shear stress estimation in the human carotid artery based on Womersley versus Poiseuille flow. International Journal of Cardiovascular Imaging, 2015, 31, 585-593.	0.7	3
41	The Value of Screening for Carotid Plaque in Patients Referred for Echocardiography. Canadian Journal of Cardiology, 2014, 30, 1148-1149.	0.8	1
42	Increasing spatial resolution of 3T MRI scanning improves reproducibility of carotid arterial wall dimension measurements. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 219-226.	1.1	21
43	A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nature Communications, 2014, 5, 3065.	5.8	336
44	Detection of Liquid Phase Cholesteryl Ester in Carotid Atherosclerosis by 1H-MR Spectroscopy in Humans. JACC: Cardiovascular Imaging, 2013, 6, 1277-1284.	2.3	12
45	Relationship of Serum Inflammatory Biomarkers With Plaque Inflammation Assessed by FDG PET/CT. JACC: Cardiovascular Imaging, 2013, 6, 1087-1094.	2.3	66
46	ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. European Heart Journal, 2013, 34, 286-291.	1.0	61
47	Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender. European Journal of Preventive Cardiology, 2012, 19, 687-697.	0.8	13
48	Safety of CETP inhibition. Current Opinion in Lipidology, 2012, 23, 518-524.	1.2	10
49	Development and Validation of an Instrument to Predict Functional Recovery in Tibial Fracture Patients. Journal of Orthopaedic Trauma, 2012, 26, 370-378.	0.7	26
50	Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis, 2012, 225, 481-485.	0.4	31
51	Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging. Journal of the American College of Cardiology, 2011, 58, 2481-2487.	1.2	58
52	Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients. JACC: Cardiovascular Imaging, 2011, 4, 1195-1205.	2.3	57
53	Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results. Journal of Clinical Epidemiology, 2011, 64, 1023-1033.	2.4	8
54	Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein-“Raising Therapies. Current Atherosclerosis Reports, 2011, 13, 277-284.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. <i>Current Medical Research and Opinion</i> , 2011, 27, 141-150.	0.9	32
56	Completeness of Carotid Intima Media Thickness Measurements Depends on Body Composition: The RADIANCE 1 and 2 trials. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 526-535.	0.9	20
57	Measuring myocardial fatty acid metabolism with BMIPP SPECT. <i>Nature Reviews Cardiology</i> , 2010, 7, 672-673.	6.1	4
58	Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 398-404.	1.3	21
59	Endothelial Shear Stress. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 578-585.	1.3	26
60	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. <i>Annals of Medicine</i> , 2010, 42, 447-464.	1.5	49
61	ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1131.	3.8	128
62	In Vivo Quantification of Carotid Artery Wall Dimensions. <i>Circulation: Cardiovascular Imaging</i> , 2009, 2, 235-242.	1.3	78
63	Use of both short musculoskeletal function assessment questionnaire and short form-36 among tibial-fracture patients was redundant. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1210-1217.	2.4	64
64	Comparison of In Vivo Carotid 3.0-T Magnetic Resonance to B-Mode Ultrasound Imaging and Histology in a Porcine Model. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 744-750.	2.3	8
65	Surrogate markers in clinical trials—Challenges and opportunities. <i>Atherosclerosis</i> , 2009, 206, 8-16.	0.4	49
66	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443.	13.9	1,180
67	Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 280-288.	3.3	221
68	Randomized Trial of Reamed and Unreamed Intramedullary Nailing of Tibial Shaft Fractures. <i>Journal of Bone and Joint Surgery - Series A</i> , 2008, 90, 2567-2578.	1.4	361
69	Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs. <i>Current Opinion in Lipidology</i> , 2007, 18, 613-621.	1.2	26
70	Tu-P9:367 Optimization of ultrasound brachial endothelial function. <i>Atherosclerosis Supplements</i> , 2006, 7, 265.	1.2	0
71	We-P14:444 Consumption of a polyphenol-rich grape extract improves the cardiovascular risk profile of healthy males. <i>Atherosclerosis Supplements</i> , 2006, 7, 444-445.	1.2	0